CoChat

World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update

Open access
Mirzayev, Fuad, Viney, Kerri, Linh, Nguyen Nhat, Gonzalez-Angulo, Licé, Gegia, Medea, Jaramillo, Ernesto, Zignol, Matteo, Kasaeva, Tereza · 2021 · European Respiratory Journal

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Antimicrobial resistance is a major public health problem globally. Likewise, forms of tuberculosis (TB) resistant to first- and second-line TB medicines present a major challenge for patients, healthcare workers and healthcare services. In November 2019, the World Health Organization (WHO) convened an independent international expert panel to review new evidence on the treatment of multidrug- (MDR) and rifampicin-resistant (RR) TB, using the Grading of Recommendations Assessment, Development and Evaluation approach. Updated WHO guidelines emerging from this review, published in June 2020, recommend a shorter treatment regimen for patients with MDR/RR-TB not resistant to fluoroquinolones (of 9–11 months), with the inclusion of bedaquiline instead of an injectable agent, making the regimen all oral. For patients with MDR-TB and additional fluoroquinolone resistance, a regimen composed of bedaquiline, pretomanid and linezolid may be used under operational research conditions (6–9 months). Depending on the drug-resistance profile, extent of TB disease or disease severity, a longer (18–20 months) all-oral, individualised treatment regimen may be used. In addition, the review of new data in 2019 allowed the WHO to conclude that there are no major safety concerns on the use of bedaquiline for >6 months’ duration, the use of delamanid and bedaquiline together and the use of bedaquiline during pregnancy, although formal recommendations were not made on these topics. The 2020 revision has highlighted the ongoing need for high-quality evidence and has reiterated the need for clinical trials and other research studies to contribute to the development of evidence-based policy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/13993003.03300-2020

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Countries that used bedaquiline for the treatment of multidrug-resistant/extensively drug-resistant tuberculosis as part of expanded access, compassionate use or under normal programmatic conditions by the end of 2019.
FIGURE 1 Countries that used bedaquiline for the treatment of multidrug-resistant/extensively drug-resistant tuberculosis as part of expanded access, compassionate use or under normal programmatic conditions by the end of 2019.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. Dooley K , Rosenkranz S , Conradie F , et al. QT effects of bedaquiline, delamanid or both in MDR-TB patients: the DELIBERATE trial. Conference on Retroviruses and Opportunistic Infections (CROI). Washington, USA. March 4–7, 2019. Available from: https://www.croiconference.org/abstract/qt-effects-bedaquiline-delamanid-or-both-mdr-tb-patients-deliberate-trial/

Cited by

See all 302

Metadata

Authors
Mirzayev, F., Viney, K., Linh, N. N., Gonzalez-Angulo, L., Gegia, M., Jaramillo, E., Zignol, M., & Kasaeva, T.
Affiliations
World Health Organization (CH)
Corresponding author
Mirzayev, Fuad
Venue
European Respiratory Journal
Published
2020-11-26
Volume
57
Issue
6
Pages
2003300
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W3108150642
Cited by
301
References
23
Citations by year
2026: 31 · 2025: 53 · 2024: 43 · 2023: 88 · 2022: 64 · 2021: 22
FWCI
2.08
Type
journal article
Language
en
Open access
Locations
  • European Respiratory Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • United States Agency for International Development
  • Russian Federation
  • Unitaid
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
Keywords
drug-resistant tuberculosis, multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis, bedaquiline, pretomanid, linezolid, delamanid, fluoroquinolone resistance, treatment duration, WHO treatment recommendations, antimicrobial resistance
MeSH terms
Linezolid, Antitubercular Agents, Drug Therapy, Combination, Female, Humans, Pregnancy, World Health Organization, Tuberculosis, Multidrug-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. https://app.cochat.ai/papers/10.1183/13993003.03300-2020
The paper
Mirzayev, F., Viney, K., Linh, N. N., Gonzalez-Angulo, L., Gegia, M., Jaramillo, E., Zignol, M., & Kasaeva, T. (2021). World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. European Respiratory Journal. https://doi.org/10.1183/13993003.03300-2020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.